Dr. Dominick Angiolillo Presents: From Dual Antiplatelet Treatment Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Low-Dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The SWAP-AC Study November 7, 2022 Disclosures: TBD
Dr. Dominick Angiolillo Presents: Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-Treatment: The SWAP-5 Study November 7, 2022 Disclosures: TBD
Dr. Jonathan Piccini and Dr. C. Michael Gibson Discuss: NOVA – Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results from the Phase 2 Nova Study November 7, 2022 Disclosures: TBD
Dr. Matthew Budoff and Dr. C. Michael Gibson Discuss: STOP – Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study November 7, 2022 Disclosures: TBA
Dr. Hyo Soo Kim and Dr. C. Michael Gibson Discuss: HOST-EXAM – Long Term Follow-Up of Aspirin vs. Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study November 7, 2022 Disclosures: TBD
Dr. Erlend Berg and Dr. C. Michael Gibson Discuss: After Eighty Study – Long-Term Outcomes of an Invasive versus Conservative Strategy in Stabilised Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomised Controlled Trial November 7, 2022 Disclosures: TBD
Dr. Carolyn Lam and Dr. C. Michael Gibson Discuss: Heart Failure Trials at AHA 2022 November 6, 2022 Disclosures: TBD
Dr. Judith Hochman and Dr. C. Michael Gibson Discuss: ISCHEMIA-EXTENDed – Follow-Up Interim Report November 6, 2022 Disclosures: TBD
Dr. Pamela Douglas and Dr. C. Michael Gibson Discuss: PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial November 6, 2022 Disclosures: TBD
Dr. Michelle O’Donoghue and Dr. C. Michael Gibson Discuss: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial November 6, 2022 Disclosures: TBD
